Literature DB >> 18490889

Coping simultaneously with 2 stressors: immigrants with ovarian cancer.

Ilana Mizrahi1, Giora Kaplan, Ellen Milshtein, Batia Piki Reshef, Gilad Ben Baruch.   

Abstract

The dual adjustment to being a cancer patient and an immigrant involves major changes in life and might be a severe experience. This study set out to describe the experience of women who have come to Israel from the former Soviet Union and are coping with ovarian cancer. It focused on illness narratives as presented by 8 patients with cancer at stage III. Our findings indicated that the dual process might have different implications according to the meaning attributed by the patient to the illness situation. Viewing the illness as one more burden among other difficulties, such as language barrier, was a prism through which patients experienced their vulnerability in coping with the illness. Alongside a helplessness pattern, we found indications of interviewees' perceiving advantages in their status as immigrant cancer patients, by dealing with that problem alongside other difficulties. They showed a "fighting spirit" in coping with the illness. Immigration can have a moderating effect on patients' experiences, and the 2 stressors do not necessarily accumulate. Our findings indicate that patients' meaning to the illness experience was a "litmus test," which indicated the way patients would describe their coping stages. This may have potential as a clinical marker of psychological vulnerability.

Entities:  

Mesh:

Year:  2008        PMID: 18490889     DOI: 10.1097/01.NCC.0000305697.20497.4f

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  1 in total

1.  Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer.

Authors:  Vanessa L Beesley; David D Smith; Christina M Nagle; Michael Friedlander; Peter Grant; Anna DeFazio; Penelope M Webb
Journal:  Support Care Cancer       Date:  2018-06-12       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.